Hemab Therapeutics company information, Employees & Contact Information

Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders PR Newswire

Hemab, working to build 'ultimate clotting company,' raises $157M series C for bleeding disorder ambitions Fierce Biotech

Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer PR Newswire

Hemab Therapeutics Presents Positive Clinical and Preclinical Data Across Bleeding Disorder Pipeline at ISTH 2025 Congress PR Newswire

Hemab collects another $157M to go after ‘underserved’ blood diseases BioPharma Dive

Novo-backed Hemab nabs $157M for blood-clotting portfolio FirstWord Pharma

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Bleeding Disorder Programs at the ISTH 2025 Congress PR Newswire

Hemab Therapeutics Appoints Kate Madigan, MD, as Chief Medical Officer citybiz

Hemab reports positive Phase I Glanzmann thrombasthenia therapy data Clinical Trials Arena

Hemab nabs $157M to finance the ‘ultimate coagulation disorder’ biotech Endpoints News

Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress PR Newswire

Hemab Therapeutics Announces Start of Velora Pioneer, a Phase 1/2 Clinical Trial Investigating HMB-002 for the Treatment of Von Willebrand Disease PR Newswire

Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders PR Newswire

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress PR Newswire

Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency PR Newswire

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia PR Newswire

Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress PR Newswire

Hemab Therapeutics Appoints John Maraganore as Chair of Board of Directors and Welcomes New Additions to Board and Leadership Team PR Newswire

Hemab Thera raises $157 million The Pharma Letter

Hemab closes $157m in funding for bleeding disorder treatments Yahoo Finance

Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders PR Newswire

Hemab Therapeutics bags US$157m in Series C financing European Biotechnology Magazine

Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders Pulse 2.0

With $135M in fresh funds, Hemab aims to leapfrog drug development for neglected blood disorders Fierce Biotech

Hemab Raises $157m To Take Lead Bleeding Disorder Drug Into Pivotal Trial Citeline News & Insights

Hemab Secures $135M for Neglected Bleeding Disorders BioSpace

Hemab doses first patient in Phase I/II trial of antibody for Glanzmann Clinical Trials Arena

Hemab raises $135 million series B for bleeding and thrombotic disorders Chemical & Engineering News

Hemab Therapeutics Raises $157M in Series C Financing FinSMEs

Blood Clotting Biotech Hemab Hauls In $135M to Drug Rare Bleeding Disorders MedCity News

Hemab raises $55M to target multiple rare bleeding indications Fierce Biotech

Turbulent global markets keep Hemab in private financing round medwatch.com

Hemab to expand its workforce after DKK 1bn investment medwatch.com

Novo Holdings and other large international investors send yet another big investment towards Danish biotech Hemab medwatch.com

First cohort dosed with potential treatment for Von Willebrand disease Pharmafile

Hemab tight-lipped on deals with Novo Nordisk and Genmab medwatch.com

Novo Holdings establishes rare bleeding disorder firm Hemab PharmaTimes

Life science companies are preparing for potential IPOs medwatch.com

Hemab co-founder to start over in cancer company medwatch.com

Denmark: Hemab closes US$135m Series B financing to support growth through 2025 Investors in Healthcare

John Maraganore is Embracing the Role of Biotech’s Newest Grandfather BioSpace

Hemophilia firm from former Novo employee secures millions from Novo Seeds medwatch.com

11 Copenhagen-based Startups you should know! StartupValley